Yale’s Ongoing Fight Against Cancer: The Cancer Center, Ongoing Research, and Louis Chenevert

Louis Chenevert is the Chairman of the Advisory Board at Yale Cancer Center

When one thinks of Yale, they automatically think of Harvard, too. Both colleges are extremely difficult to be accepted in. Both are located in the New England area in the northeast coast of the United States as well.

While Yale is considered to have a better undergraduate program, Harvard is thought to have a better graduate program. Yale is one of the top fine arts schools, having both great music and drama programs. Harvard is considered one of the very top business schools.

Just as important is both have cancer centers that do a lot of research in determining ways to battle cancer. For those that have lost loved ones to cancer, it provides comfort in knowing some of the brightest are working on cures. And for those that are currently staring cancer down, the breakthroughs cannot come quick enough.


The Yale Cancer Center was started in 1974 after Congress began a “War on Cancer” edict in 1971. It brings together all the knowledge and resources of Yale Medicine, Smilow Cancer Hospital, and Yale University. It was over sixty years ago that Yale Medicine developed the modern concepts that led to chemotherapy being administered to a person with cancer.

The anticancer agent that was used by Yale Medicine was nitrogen mustard. While in controlled doses, it can indeed be a chemotherapy agent. In higher doses, it could be used in chemical warfare. But with all the medical research that has been done throughout the years, there are numerous options available for battling cancer.

The Yale Cancer Center’s goal is to offer high quality clinical care by using their promising research in cancer treatments. This means that patients may have early access to treatments and discoveries that are not yet available at other hospitals and cancer centers. The innovative therapies provided for cancer patients are all due to their untiring research and studies they have conducted. In fact, Yale Cancer Center has 64 current clinical trials available for patients with early or late stage diseases.

The Research

Interestingly enough, Yale School of Medicine was home to the first university-based Oncology Section. Oncology is the study and treatment of tumors. And the faculty there has pioneered breakthrough cancer research and treatments over the years.

The research of cancer brings in about $140 million of funding to Yale every year. Because of this, Yale has been able to bring in a few of the world’s leading cancer researchers. They are able to lead the way with a number of advances and approaches to treating cancer effectively.

The Yale Cancer Center focuses on seven different research programs.

  • They have Developmental Therapeutics which provides services and resources to the research communities to facilitate the discovery and development of new cancer therapeutic agents.
  • Cancer Genetics and Genomics which looks at the genes that people inherit.
  • Cancer Immunology which focuses on the immune system and how it handles cancer.
  • The Molecular Virology research program is the study of viruses at the molecular level.
  • Prevention and Control looks at effective strategies in preventing cancers and what works best for controlling them as well.
  • The Radiobiology and Radiotherapy program handles research effort in radiation therapy, radiation biology, radiological physics, and even areas of tumor biology. They also research DNA damage and repair.
  • The last of the research programs, Signal Transduction, focuses on the cancer cell itself.

Advisory Board

Louis Chenevert is a Dedicated Member of the Board

The Yale Cancer Center Director’s Advisory Board is a group of volunteers who are knowledgeable about the Center’s mission. They are advocates for the Center and promote the goals whenever needed. They also participate greatly in fundraising so the Center has the funds to continue their extraordinary research.

Louis Chenevert (who we’ve written about here) serves as the Chairman of the Advisory Board at Yale Cancer Center. Chenevert retired a few years ago from being president and CEO of United Technologies Corporation (UTC). UTC, known well for their aerospace systems, is about a $100 billion company. During his time there, he greatly improved UTC across the board and turned them into a juggernaut in many areas. Louis Chenevert is used to dealing with finances through his business experience at UTC. His work at UTC has improved the lives of thousands of employees and their families. But the situations that Yale Cancer Center deals with everyday are life and death. Being able to help them raise the money needed to continue their research is not something he takes lightly.

“Yale Cancer Center is a critical asset in the fight against cancer, a disease that unfortunately still touches nearly every family,” said Chenevert. “I’m proud to work with the Advisory Board to ensure Yale Cancer Center and its talented staff have the resources needed to deliver life-saving care to families throughout our region.”

Since 2001, Louis Chenevert has been part of the Advisory Board. He was also a co-chairman for the Campaign Committee for Smilow Cancer Hospital from 2007 to 2010. It is obvious he is interested in helping those that are battling cancer, and provide hope for their families as well.

“Louis has been a tremendous supporter of Yale Cancer Center over the last decade and shares our continued commitment to ensuring that residents of Connecticut have access to the newest cancer therapies and best care possible. I am honored to have his leadership as Chair of our Advisory Board,” said Thomas J. Lynch, MD, Director of Yale Cancer Center and Physician-in-Chief of Smilow Cancer Hospital at Yale-New Haven.

With the continued work of over the 350 scientists and physicians at Yale Cancer Center, they are sure to make world-changing discoveries in the treatment and, hopefully, the eventual cure of cancer. In a perfect world, with the funding provided them and many other cancer centers and hospitals around the globe, cancer will someday be a forgotten word in our history.

About Erica Smith 261 Articles
With several years in the medical field—both as a practitioner and an administrator—Erica has a unique perspective on the health industries. From medical technology to cancer research, she covers our health industry.

Be the first to comment

Leave a Reply

Your email address will not be published.